Senicapoc treatment in COVID-19 patients with severe respiratory insufficiency-A randomized, open-label, phase II trial.

ABSTRACT:

Background

The aim of the current study was to determine if treatment with senicapoc, improves the PaO₂ /FiO₂ ratio in patients with COVID-19 and severe respiratory insufficiency.

Methods

Investigator-initiated, randomized, open-label, phase II trial in four intensive care units (ICU) in Denmark. We included patients aged ≥18 years and admitted to an ICU with severe respiratory insufficiency due to COVID-19. The intervention consisted of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 h. Patients in the control group received standard care only. The primary outcome was the PaO₂ /FiO₂ ratio at 72 h.

Results

Twenty patients were randomized to senicapoc and 26 patients to standard

SUBMITTER: Granfeldt A 

PROVIDER: S-EPMC9111301 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature